New national guidelines can improve the way
statin drugs are prescribed to patients at risk for cardiovascular disease, a
Yale University study has found.
The research, published Aug. 25, 2014 in the
Journal of the American College of Cardiology, also showed the new
guidelines produce only a modest increase in the number of patients being given
the drugs.
Statins are a class of drugs that help lower
cholesterol by blocking the enzyme HMG-CoA reductase, which the body needs in
order to produce cholesterol. Common statin medications include Lipitor,
Levacor, Zocor, Pravachol, and Crestor.
In 2013, the American Heart Association and
the American College of Cardiology jointly published a new set of standards for
the assessment of cardiovascular risk. The standards replaced the 2001 National
Cholesterol Education Program Adult Treatment Panel III recommendations.
"There has been a great deal of
discussion about the new guidelines. People worry whether the new risk equation
is accurate," said Dr. Kevin M. Johnson, lead author of the study and
associate professor of diagnostic radiology at the Yale School of Medicine.
"They are concerned that too many people will be put on statins."
Johnson and co-author Dr. David A. Dowe of
Atlantic Medical Imaging, in Galloway, N.J., studied 3,076 subjects. They
applied both sets of guidelines to determine whether patients would start
statin therapy.
They found that the new guidelines did a
better job of discriminating between patients with little or no plaque and
those with more plaque. Of patients with heavy plaque, 92% would be assigned to
statin therapy under the new method, but only 53% under the old standards.
The biggest difference between the two
results, researchers said, was the use of low-density lipoprotein (LDL)
cholesterol targets under the old guidelines. The targets "seriously
degraded the accuracy of the NCEP guideline for statin assignment,"
according to the study.
"The old guidelines emphasized lowering
LDL cholesterol to certain target values, but the new guidelines have done away
with that approach," Johnson said. "Many doctors are reluctant to
give up targets."
Overall, 15% more patients would be put on
statins under the new guidelines — considerably fewer than some observers had
predicted, he added.
The researchers noted that they used
coronary atherosclerotic plaque burden as the determining factor in the study,
rather than cardiac events. Further study will be necessary to evaluate the
guidelines with outcome data.
No comments:
Post a Comment